Contents
Current Pharmaceutical Design, Volume 17 - Number 2
Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
, 17(2): 94 - 102Shigeyuki Chaki and Hirohiko Hikichi
DOI: 10.2174/138161211795049570
Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia
, 17(2): 103 - 111Dana V. Ferraris and Takashi Tsukamoto
DOI: 10.2174/138161211795049633
α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia
, 17(2): 121 - 129Masatomo Ishikawa and Kenji Hashimoto
DOI: 10.2174/138161211795049561
Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
, 17(2): 130 - 136Norbert Muller, Aye-Mu Myint and Markus J. Schwarz
DOI: 10.2174/138161211795049552
PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
, 17(2): 137 - 150Jan Kehler and Jacob Nielsen
DOI: 10.2174/138161211795049624
Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
, 17(2): 151 - 167Silvia Paba, Roberto Frau, Sean C. Godar, Paola Devoto, Francesco Marrosu and Marco Bortolato
DOI: 10.2174/138161211795049589
Role of Polyunsaturated Fatty Acids and Fatty Acid Binding Protein in the Pathogenesis of Schizophrenia
, 17(2): 168 - 175Motoko Maekawa, Yuji Owada and Takeo Yoshikawa
DOI: 10.2174/138161211795049615
MicroRNAs: A Novel Therapeutic Target for Schizophrenia
, 17(2): 176 - 188Javier A. Bravo and Timothy G. Dinan
DOI: 10.2174/138161211795049543
Webmaster Contact: info@benthamscience.org